LAPORTE KATHLEEN 4

What Happened
Kathleen LaPorte, a director of Bolt Biotherapeutics, was granted a derivative award for 5,000 shares on June 10, 2026. The Form 4 lists the acquisition price as $0.00, indicating no cash was paid at grant; the transaction is recorded as an award/grant (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 11, 2026 (timely filing).
• Transaction type/code: A — Grant/Award (derivative).
• Shares involved: 5,000 shares granted at $0.00; immediate reported value $0.
• Vesting note: The award vests on the earlier of June 9, 2027 or the day before the next annual meeting, subject to continuous service; it vests in full upon a change in control.
• Shares owned after transaction: not specified in the filing.

Context
This is a compensatory grant (commonly RSUs or similar) rather than a purchase, so it reflects company compensation practices rather than an out-of-pocket investment by the director. The vesting schedule ties the award to continued service and provides acceleration on a change in control. The prompt filing the next day indicates no late-reporting issue.